Olanzapine LA-Rest AP

From Psychiatrienet
Revision as of 14:27, 26 August 2009 by Verena (talk | contribs)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to: navigation, search
Olanzapine
long acting
Type Antipsychotic
Group Atypical AP
links
Medscape Olanzapine
EMEA zypadhera
PubChem 4585
PubMed Olanzapine
Kompas (Dutch) Olanzapine
Wikipedia Olanzapine
Rest anti-psychotics

Chlorprothixene
Flupentixol
Loxapine
Pericyazine
Perphenazine
Trifluoperazine
Ziprasidone
Zuclopenthixol

Switch medication from Olanzapine_LA to Rest AP.[1] [2]

Nietinrijdenbord.png Stop Olanzapine_LA
  • Day 1: Last depot injection
Eenrichtingbord.png Start Rest AP
  • Week 1-3: approx. 25% of target dose
  • Week 4-6: approx. 50% of target dose
  • Week 7-9: approx. 75% of target dose
  • Week 10: target dose
Infobord.png More information
  • During this switch you could monitor ECG, especially in patients prone to QT-conduction problems.
  • There is a possibility of QT interval prolongation.[3]
    StopDepotStartOral.jpg
Nietinrijdenbord.png — Olanzapine_LA
Eenrichtingbord.png — Rest AP


  1. Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
  2. Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
  3. Stöllberger C, Huber JO, Finsterer J, Antipsychotic drugs and QT prolongation. Int Clin Psychopharmacol. 2005 Sep;20(5):243-51.
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.